The prevalence of several respiratory diseases decreased with the use of SGLT2 inhibitors, including acute pulmonary edema, bronchitis, chronic obstructive pulmonary disease, asthma, non-small cell lung cancer, pleural effusion, pneumonia, pulmonary edema and masses, respiratory tract infections, and sleep apnea syndrome [43]. Here, SLC5A2 is linked to pulmonary edema.